HKSE:9606
Duality Biotherapeutics, Inc. · HKSE · Healthcare · HKD · FY for 2025
Figures on this page computed 2026-11-08 10:07 UTC
Last close
n/aHKD
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-136.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
9.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Growth is the furthest below its sector's middle: 0.13 against 0.46 on the market's range.
- Growth-140.6%13 of 100, below its sector
- Returns on capital-104.2%10 of 100, below its sector
- Margins31.1%37 of 100, above its sector
- Price2.4x37 of 100, below its sector
- Safety3.6159 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.33x
Its own average over 4 years, 1.40B.
- Profit2.34x
Its own average over 4 years, -1.08B.
- Free cash flow0.81x
Its own average over 4 years, 223.6M.
- Debt3.63x
Its own average over 4 years, 41.3M.
- Pricen/a
Its own average over 0 years. Market data
Debt is furthest from its own average, at 3.63 times.
It reports in CNY and trades in HKD. Nothing on this page is converted between the two.
The filed years, as a table
4Each line is 100 at 2022-12-31, the first year we hold.
| Filed year | Sales | Shares in issue |
|---|---|---|
| 2022-12-31 | 100.0 | 100.0 |
| 2023-12-31 | 111,658.8 | 100.0 |
| 2024-12-31 | 121,328.6 | 100.0 |
| 2025-12-31 | 115,733.4 | 78.3 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
-140.6%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
One-year change in net income-140.6%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Returns on capital
-104.2%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity-104.2%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets-64.9%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
31.1%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin31.1%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin-23.1%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin-136.5%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin9.8%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
2.4xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
Price to book2.4x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio3.1x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
3.61safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.61
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score1.59
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
n/aWe do not hold this figure for this company, so there is nothing to place.
more, and better covered, is higher, with no cohort held
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.